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In a randomized, controlled study of ribavirin aerosol treatment of influenza A(HlNl) virus infection among
college students, treated patients had a significantly shorter duration of fever than control patients. There was a
trend of more rapid recovery in treated patients. Virus shedding was similar in treated and control patients,
declining gradually from a 50% tissue culture infective dose of 3.5 log,0 per ml at admission to 1.8 logl0 per ml
at 53 h after admission. There was po local or systemic intolerance and no hematological or biochemical
abnormalities associated with ribavirin treatment.
Ribavirin, 1-3-D-ribofuranosyl-1,2,4-triazole-3-carbox-
amide, a broad-spectrum antiviral agent, has been used
successfully to treat respiratory syncytial virus infection in
children (6, 10) and respiratory syncytial virus and parainflu-
enza virus infections of immunodeficient children (5) by
aerosol. We previously described the therapeutic efficacy of
ribavirin small-particle aerosol in the treatment of influenza
A/England/333/80(HlN1) virus infection in college students
(7). In that study, fever and illness disappeared more rapidly
and virus shedding was less in treated patients than in
control patients.
In February and March 1982, an outbreak of influenza
occurred again in the same location, and a randomized,
controlled study was made of ribavirin aerosol in its treat-
ment. When diagnostic studies became available, it was
learned that the outbreak had consisted of about equal
numbers of patients with influenza A(HlN1) virus and
influenza B virus infections. The present report will describe
the findings in the treatment of patients with influenza
A(H1N1) virus infection; the favorable results of the treat-
ment of influenza B virus infection with ribavirin aerosol
have been presented elsewhere (8).
MATERIALS AND METHODS
Patients. Fifty-four students with a clinical syndrome
resembling influenza of <24-h duration and with fever
.101'F volunteered for a randomized, controlled study of
influenza treatment. After signing consent forms approved
by the institutional review boards of Texas A & M Universi-
ty and Baylor College of Medicine, they were assigned to
treated or control groups by a code derived from a table of
random numbers. Control patients received sterile saline by
aerosol. Patients were not informed whether they were to
receive ribavirin or saline aerosol.
The etiology of the infection of these patients based on
virus isolation was not known until after completion of
treatment. Viral diagnostic studies ultimately revealed that
19 patients had influenza A/England/333/80-like virus infec-
tion, of which 8 were treated and 11 were controls. Twenty-
one other patients proved to have influenza B/Singapore/222/
79-like virus infection, two others had a picornavirus, and
one had varicella virus. The remaining 11 were undiagnosed.
Four of eight treated patients and 5 of 11 control patients
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were women. One treated patient was of hispanic origin and
one control patient was oriental. Six treated and 10 control
patients reported having had influenza within the past 2
years. One control patient reported receiving an influenza
vaccination within 2 years. The mean age of treated patients
was 20.8 years, and that of control patients was 21.2 years.
Except for one control patient who was 28 years of age,
patients in both groups ranged in age from 18.7 to 23.2 years.
A pregnancy test and a careful history revealed no women
with evidence of pregnancy.
Aerosol-producing system. A Collison generator operated
by compressed air was designed to operate continuously
with an aerosol flow of 12.5 liters/min with an average
ribavirin concentration of 190 ,ug/liter of air. This concentra-
tion of ribavirin is slightly greater than previously reported
due to an improved method of circulation of the drug
solution between the aerosol generator and the fluid reser-
voir (8). The particle size was 1.3 microns mass median
diameter, with 95% of the particles <5 microns in diameter.
The aerosol generator was connected to a Puritan Benefit
Mask worn by the patient by means of smooth-flow Corr-A
type II tubing. Treatment was begun within 1 h of admission
and continued for 16 h continuously or until 6:00 a.m. the
following morning, whichever came first. The following
morning all participants were treated on a regular schedule
for 4 h continuously, commencing at 7:00 a.m., 1:00 p.m.,
and 7:00 p.m. Treatment was continued through the first 4-h
period on day 3. The retained dose of ribavirin was calculat-
ed as follows: the mean minute volume (liters) for each
patient (2) each day was multiplied by 0.19 mg (mean
ribavirin aerosol concentration per liter) times 60 min times
the number of hours of treatment each day times 0.7
(estimated fraction of inhaled aerosol deposited in the respi-
ratory tract) as previously described (8; B. E. Gilbert, S. Z.
Wilson, V. Knight, R. B. Couch, T. L. Melhoff, H. W.
McClung, G. W. Divine, D. D. Bartlett, L. C. Cohan, and
T. L. Gallion, in R. A. Smith, V. Knight, and J. Smith (ed.),
Clinical Aspects of Ribavirin, in press). This calculation
gives the estimated milligrams of ribavirin retained per day
for each patient.
Assessment of illness and fever. A detailed clinical assess-
ment of each patient was made on admission and daily at
8:00 a.m. and 5:00 p.m. thereafter until discharge. The
details of this examination were described in our previous
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tion, concentrating on respiratory tract disease, were made
and recorded on a form designed for computer input. At the
conclusion of each exam, the illness of the patient was
scored with a range of 0 to 3+ (increasing severity) accord-
ing to the categories of rhinitis, pharyngitis, tracheobronchi-
tis, pneumonia, and systemic illness. As in previous studies,
systemic illness characterized by prostration, anorexia,
headache, and muscle aches was the most prominent feature
of the illness. Patients who remained confined to bed except
for bathroom activities and were profoundly prostrated were
classified as 3+ severity. Those remaining essentially bed-
ridden but with less prostration were classified as 2+ sever-
ity; the major activity of this group was watching television.
Students not yet asymptomatic but who were ambulatory
were classified as 1+. Patients were assigned to one of four
physicians for their care and evaluation. As in previous
studies, each physician was trained for this assignment by a
senior clinician (H. McC.) who also supervised their treat-
ment and evaluation of patients (7, 8). Physicians were
aware of the treatment status of patients. The patients were
not informed of their treatment status until discharge from
the hospital. Oral temperatures were taken by nurses every 4
h. Antipyretics were not routinely available; however, two
treated and two control patients received a single dose of
acetaminophen for temperatures exceeding 103.5°F.
Clinical laboratory studies. The following automated bio-
chemical observations were made on serum at admission,
discharge, 1 week after discharge, and 1 month after dis-
charge: sodium, potassium, chloride, calcium, phosphorus,
urea, creatinine, uric acid, cholesterol, triglycerides, total
protein, globulin, albumin, glucose, total bilirubin, direct
and indirect bilirubin, alkaline phosphatase, aspartate amino-
transaminase, alanine transaminase, lactic dehydrogenase,
and gamma glutamyltransaminase.
Hematological studies consisted of hematocrit, hemoglo-
bin, mean cell volume, and leukocyte count with differential
and platelet count. Serum for acute and convalescent anti-
body titration was stored at -20°C. Throat swabs for bacte-
ria and chest roentgenograms were obtained at admission.
Virus isolation and quantification. A throat swab was
collected at admission in veal infusion broth containing
penicillin and streptomycin and subjected to standard virus
diagnostic procedures (3). The initial isolates from all 19
patients in this study exhibited specific immunofluorescence
with influenza A/Brazil/11/78(HlN1) virus (1, 4). Subsequent
analysis (see below) of antibody response of the patients
suggested that these strains were most closely related to
influenza A/England/333/80(HlN1).
Quantification of virus in nasal secretions was performed
in 24-well microtiter plates containing MDCK cell culture by
a method described previously (7). Titers were calculated by
the method of Karber (9) and are reported as the 50% tissue
culture infective dose (TCID50) per milliliter of original nasal
wash. In the previous report (7), they were given as TCID50
per 0.1 ml.
Hemagglutination inhibition-antibody titration. Specimens
from acutely ill and convalescent patients were titrated in
plastic dishes with 8 rows, each containing 12 0.25-ml
conical wells (Linbro-Titerek, Hamden, Conn.), by a stan-
dard method (3). Three antigens, A/England/333/80(HlN1),
A/Brazil/11/78(HlN1), and A/Texas/13/81(HlN1) were used
in the tests. There was a high degree of cross-reactivity with
the three antigens, but there was a slight predominance of
reactivity with influenza A/England/333/80(HlN1).
Statistical analysis. The Student's t test and the Wilcoxon
rank sum test were used as described below.
Susceptibility of clinical isolates to ribavirin. To determine
whether clinical isolates of influenza virus varied significant-
ly from year to year in their susceptibility to ribavirin, 61
samples obtained over a 3-year period from patients in our
studies at Texas A & M University were tested. Pre- and
posttreatment influenza virus isolates were passaged once
from tissue culture harvests (1981 and 1982) or from nasal
wash specimens (1983) into embryonated eggs. Egg pools
were collected and virus was quantitated (TCID50 per millili-
ter) as previously described (7). Drug sensitivity was deter-
mined by addition of 10 TCID50 (0.1 ml) of virus to confluent
monolayers of MDCK cells, adsorption for 1 h at 34°C, and
replacement of the inoculum with fresh minimal essential
medium with Worthington trypsin (2 .ag/ml) containing 0, 10,
20, 30, 40, 60, 80, or 100 p.M ribavirin (three wells per
dilution). After 3 days of incubation at 34°C, the presence of
viral replication at each dilution of ribavirin was determined
by the hemadsorption of guinea pig erythrocytes (0.075%) at
4°C. The TCID50 of ribavirin was calculated by plotting the
number of positive wells showing hemadsorption against the
log of the ribavirin concentration. In addition, the MIC of
ribavirin was determined as the last well not demonstrating
hemadsorption. A standard laboratory strain of influenza A/
Bangkok/1/79(H3N2) was assayed with each replicate set of
tests. The TCID5o determined for eight assays was 32.5 ±
28.2 ,uM. Probability (P) values were calculated by the
Student's t test, two-tailed.
RESULTS
Febrile response in treated and control patients. Nineteen
patients had influenza A(HlNl) virus infection, of which 11
were controls and 8 were treated. The mean time of illness
before treatment was 2.25 h greater in control than in treated
patients (17.00 and 14.75 h, respectively), a difference great-
er than in previous studies. The period from the start of
treatment to a sustained afebrile state was less in treated
(31.4 h) than in control (42.7 h) patients but was of borderline
significance. However, if the calculation is made from onset
of illness to the sustained afebrile state (<100'F), the differ-
ence is significant (treated: 46.1 h; control: 59.7 h; P = 0.045,
Student's t test, two tailed).
In Table 1, the mean maximum daily temperatures for
treated and control patients show a trend to lower tempera-
ture in treated patients on day 2.
Illness in treated and control patients. Table 2 shows the
assessment of rhinitis and systemic illness in treated and
control patients. Rhinitis was more severe before treatment
in control patients and, thereafter, was about equal in the
two groups until day 2 when treated patients improved more
rapidly than control patients. Systemic illness was about the
same severity in treated and control patients except on the
afternoon of day 2 when it was significantly less in treated
patients. In both groups, the p.m. values on day 2 were
inconsistently low. Tracheobronchitis and pharyngitis were
not severe, and there were no significant differences be-
tween treated and control patients. There was no pneumonia
in either group.
Virus shedding in treated and control patients. All 19
patients had influenza A(HlN1) virus isolated from a throat
swab at admission. In one treated patient, however, virus
shedding was never detected in any of the nasal wash
specimens. Virus titers in treated and control groups de-
clined from a mean TCID50 of 3.5 loglo per ml at admission to
1.8 log1o per ml at 53 h after admission. Virus titers of nasal
secretions obtained from treated and control patients at













TABLE 1. Mean maximum daily temperatures in treated and
control patients
Patient group Mean maximum daily temp (°F) on day:
(no.) 0 1 2 3
Treated (8) 103.1 102.8 99.4 98.2
Control (11) 102.9 102.2 100.3 98.4
P- value 0.150a 0.106 0.070 0.150
a Student's t test, one-tailed.
not significantly different (P > 0.3; Student's t test, two-
tailed).
Hemagglutination inhibition antibody titers of treated and
control patients. The geometric mean serum antibody titer to
influenza A/England/333/80 at the time of admission was
1:2.8 and 1:2.7 in treated and control patients, respectively,
whereas 1 month later the titers in treated and control
patients were 1:13 and 1:21, respectively. The differences in
titers in treated and control patients at admission or in
convalescence were not statistically significant (Wilcoxon
rank sum test, two-tailed).
Hematological findings. The hematological profiles in
treated and control patients were very similar at all times.
The leukocyte series revealed the expected low normal
values at onset of this illness. At discharge, total counts were
still lower due to a further reduction in polymorphonuclear
cells. Absolute lymphocyte counts were lowest at admission
and increased slightly thereafter. Platelet counts remained
within a normal range throughout the study. The hematolog-
ical findings in both groups reflect the normal course of
influenza infection.
Biochemical tests in treated and control patients. The mean
values of 22 biochemical tests in treated and control patients
were within a normal range. Some differences in means
within a normal range were encountered that approached
significance. These were examined individually (triglycer-
ides, albumin, and gamma glutamyltransaminase) and con-
sidered to be of no clinical significance.
Ribavirin aerosol dosage. Table 3 shows the estimated
retained dosage of ribavirin. From the table, it can be
calculated that the dose per hour of treatment per patient
was 51.6 mg or 0.79 ± 0.04 mg/kg per h. The total dose was
1.9 g during 37.3 h of treatment, largely administered during
the first 60 h in the hospital. This is very similar to dosages of
ribavirin aerosol in other studies (7, 18). There was no local
or systemic intolerance to the treatment.
Susceptibility of influenza viruses to ribavirin. Pre- and
posttreatment influenza virus isolates from 3 consecutive
TABLE 2. Rhinitis and systemic illness in treated and control
patients
Range of severity (mean score) on day:
Illness in patient 1 2 3
group o
a.m. p.m. a.m. p.m. a.m. p.m.
Rhinitis
Treated 0.9 1.6 1.5 1.0 0.6 0.5 0.5
Control 1.7 1.6 1.6 1.5 1.5 1.1 1.0
P valuea 0.025 0.43 0.28 0.070 0.002 0.042 0.060
Systemic illness
Treated 2.4 2.3 1.8 1.8 0.5 1.5 0.3
Control 2.4 2.5 1.6 1.5 0.9 1.8 0.5
P value' 0.463 0.175 0.428 0.186 0.026 0.138 0.204
a Wilcoxon rank sum test, one-tailed.
TABLE 3. Estimated mean retained dose of ribavirin
No. of No. of h Estimated mean retained
Day patients administered dose of ribavirin
receiving per day mg/day mg/kg per day
0 7 4.7 251 3.7
1 8 18.3 998 14.8
2 8 11.3 564 8.4
3 1 3.0 112 2.5
years of observation of the college students were tested for
susceptibility to ribavirin. Among influenza B virus isolates
in 1982, the TCID50 in posttreatment specimens was about
twofold greater than in the pretreatment specimens (Table
4). Influenza A virus isolates during the 3 years did not show
an increase in the inhibitory concentration of ribavirin in
posttreatment specimens, nor was there any difference in
isolates obtained from control or treated patients. In a
limited number of paired pre- and posttreatment samples,
ribavirin susceptibility was similar (data not shown).
DISCUSSION
This study has described a favorable effect of ribavirin
aerosol in the treatment of influenza A(HlN1) virus infection
in a group of college students. Fever, systemic illness, and
rhinitis improved more rapidly in treated patients than in
randomly selected control patients who were given saline
aerosol.
Virus disappeared from nasal wash fluids at about the
same rate in treated and control patients. This is in contrast
to results of a previous study of influenza A(HlN1) virus
infection a year earlier at the same site and a study of
influenza B virus infection concurrent with the present study
(7, 8). Virus titrations of nasal secretions in the present
influenza A(HlN1) study were performed >6 months after
the specimens were collected, and the treated and control
patients, though randomly selected, were not equal in num-
ber. Moreover, the mean periods of illness before treatment
were dissimilar, both variations being introduced because of
the unanticipated occurrence of both influenza A(H1N1)
virus and influenza B virus infections in the same outbreak.
These events may have influenced virus shedding patterns.
As in two other studies of the treatment of influenza (7, 8),
there was no detectable respiratory intolerance, and no
hematological, liver function, or blood chemical abnormali-
ties associated with treatment.
The limited therapeutic effect was apparently not the
result of increased resistance of the virus to treatment. The
only increase in resistance to ribavirin after treatment oc-
curred in influenza B isolates and that increase was not
considered to be of clinical significance. The variations in
susceptibility and in the standard deviation were most likely
due to variations inherent in virus quantification. Since drug
susceptibility to ribavirin is virus concentration dependent,
errors in 10-fold dilutions of virus used to calculate the
appropriate TCID50 values (i.e., ±+0.25 log10) would be
reflected in two- or threefold errors in determining drug
susceptibility levels.
We have noted elsewhere (Gilbert et al., in press) that the
duration of illness with influenza A(HlN1) virus infection is
less than that with influenza A(H3N2) or B virus infection.
Thus, there is less time in which to show a therapeutic effect.
In 1981, despite a short duration of illness with A(HlN1)
infection, the ribavirin aerosol treatment was quite effective
(7). The shorter period of illness may be part of the explana-











RIBAVIRIN AEROSOL TREATMENT OF INFLUENZA 203
TABLE 4. Susceptibility of clinical isolates of influenza virus to ribavirin
TCID50 (puM ± SD)- P valueb
Virus Year (pre- vs
Pretreatment Posttreatment All isolates posttreatment)
H3N2 1983 39.6 ± 12.7 (5) 39.6 ± 12.7 (5)
B 1982 40.6 ± 10.4 (5) 78.6 ± 32.2 (8) 64.0 ± 31.8 (13) 0.032
HlNl 1983 57.0 ± 30.2 (7) 42.4 ± 15.0 (7) 49.7 ± 24.2 (14) 0.279
1982 42.8 ± 38.7 (6) 58.7 ± 32.4 (6) 53.4 ± 34.5 (12) >0.6
1981 39.8 ± 36.3 (17) 39.8 ± 36.3 (17)
"Number of isolates tested.
bStudent's t test, two-tailed.
tion for the limited therapeutic effort observed in the present
study, but additional factors may contribute.
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